Literature DB >> 12951555

Gadobenate dimeglumine (Gd-DTPA) vs gadopentetate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio.

Federica Pediconi1, Francesco Fraioli, Carlo Catalano, Alessandro Napoli, Massimiliano Danti, Marco Francone, Fiammetta Venditti, Piergiorgio Nardis, Roberto Passariello.   

Abstract

PURPOSE: The purpose of this study was to compare contrast enhanced MR angiography (MRA) with gadopentetate dimeglumine (Gd-DTPA) to MRA with gadobenate dimeglumine (Gd-BOPTA), a high relaxivity paramagnetic contrast agent.
MATERIALS AND METHODS: Twelve patients referred for carotid artery stenosis were examined with MR angiography using a fast spoiled gradient echo sequence. Gd-DTPA and Gd-BOPTA enhanced MR angiography were performed within 48-72 hours using a dose of 0.1 mmol/kg for Gd-BOPTA and 0.2 mmol/kg for Gd-DTPA, at a flow rate of 2 ml/s. Images were evaluated by two blinded radiologists. Qualitative and quantitative evaluations were performed comparing the sets of images from the two examinations.
RESULTS: Qualitative evaluation demonstrated superior arterial contrast enhancement and vessel conspicuity with Gd-BOPTA compared with Gd-DTPA. Quantita-tive evaluation showed an improvement in both signal intensity and contrast to noise ratio with Gd-BOPTA.
CONCLUSION: The greater relaxivity of Gd-BOPTA, at lower doses, compared with Gd-DTPA, provides higher intravascular signal and signal to noise ratio. Gd-BOPTA appears to be an optimal contrast agent for contrast enhanced MRA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12951555

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  9 in total

Review 1.  Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence.

Authors:  E Kanal; K Maravilla; H A Rowley
Journal:  AJNR Am J Neuroradiol       Date:  2014-05-22       Impact factor: 3.825

2.  Diagnostic accuracy of colour Doppler ultrasonography, CT angiography and blood-pool-enhanced MR angiography in assessing carotid stenosis: a comparative study with DSA in 170 patients.

Authors:  M Anzidei; A Napoli; F Zaccagna; P Di Paolo; L Saba; B Cavallo Marincola; C Zini; G Cartocci; L Di Mare; C Catalano; R Passariello
Journal:  Radiol Med       Date:  2011-03-07       Impact factor: 3.469

Review 3.  High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review.

Authors:  Frederik L Giesel; Amit Mehndiratta; Marco Essig
Journal:  Eur Radiol       Date:  2010-06-23       Impact factor: 5.315

4.  Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-aortic arteries (the Supra-Aortic VALUE study).

Authors:  Yanjun Li; X Li; D Li; J Lu; X Xing; F Yan; Yuan Li; X Wang; R Iezzi; F De Cobelli
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-04       Impact factor: 3.825

5.  Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.

Authors:  Guenther Schneider; Hellmut Schürholz; Miles A Kirchin; Arno Bücker; Peter Fries
Journal:  Pediatr Radiol       Date:  2012-11-24

6.  Follow-up of coiled cerebral aneurysms at 3T: comparison of 3D time-of-flight MR angiography and contrast-enhanced MR angiography.

Authors:  N Anzalone; F Scomazzoni; M Cirillo; C Righi; F Simionato; M Cadioli; A Iadanza; M A Kirchin; G Scotti
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-12       Impact factor: 3.825

7.  Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?

Authors:  M A Kirchin; V Lorusso; G Pirovano
Journal:  Br J Radiol       Date:  2015-02-04       Impact factor: 3.039

8.  Low-dose gadobenate dimeglumine-enhanced MRI of the kidney for the differential diagnosis of localized renal lesions.

Authors:  Guenther Schneider; Thorsten Probst; Miles A Kirchin; Jonas Stroeder; Peter Fries; Arno Buecker
Journal:  Radiol Med       Date:  2015-06-19       Impact factor: 3.469

9.  Gdn 3+@CNTs-PEG versus Gadovist®: In Vitro Assay.

Authors:  Ghazal Mehri-Kakavand; Hadi Hasanzadeh; Rouzbeh Jahanbakhsh; Maryam Abdollahi; Reza Nasr; Ahmad Bitarafan-Rajabi; Majid Jadidi; Amir Darbandi-Azar; Alireza Emadi
Journal:  Oman Med J       Date:  2019-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.